Selectively reduces H3K27 methylation by EZH2 in vitro and in lymphoma cell-based models. Treatment of lymphoma cells bearing a mutant EZH2, leads to antiproliferative effects, indicating that these cancers are critically dependent on mutant EZH2. This evidence concerns the gene EZH2 and cancer.